"The CDA allows the two companies to discuss publicly undisclosed information about NanoViricides' drug development against SARS-CoV-2 to treat COVID-19 that is currently a worldwide pandemic."
So it allows the two companies to discuss publicly undisclosed information. And it allows the two companies to discuss undisclosed information publicly.